

**IND SAFETY REPORT: INITIAL WRITTEN REPORT**

**TO: Division of Biologic Oncology Products, Center for Drug Evaluation and Research, FDA**

**FAX: 301-796-9849**

1. IND NUMBER <b>7921</b>	2. AGENT NAME <b>Bevacizumab (rhuMAb VEGF)</b>	3. DATE <b>April 7, 2011</b>
4. SPONSOR <b>Division of Cancer Treatment and Diagnosis, National Cancer Institute</b>		
5. REPORTER'S NAME, TITLE, AND INSTITUTION <b>Helen Chen, MD-Associate Branch Chief for Investigational Therapeutics 3, Investigational Drug Branch, CTEP, DCTD, NCI</b>		6. PHONE NUMBER <b>301-496-1196</b>
		7. FAX NUMBER <b>301-402-0428</b>
8a. PROTOCOL NUMBER (AE #) <b>CALGB-90601 (AE # 1740963)</b>	8b. AE GRADE: AE <b>Grade 5: Death NOS</b>	
9. PATIENT IDENTIFICATION <b>122341</b>	10. AGE <b>50 yrs</b>	11. SEX <b>Male</b>
12. DESCRIPTION OF ADVERSE EVENT <b>The patient was a 50-year-old male with transitional cell carcinoma of the urothelial tract who expired while on a phase 3 trial utilizing the investigational agent bevacizumab/placebo in combination with cisplatin and gemcitabine. He began the first dose of the investigational therapy on September 9, 2010, and received the last dose of bevacizumab/placebo on March 3, 2011 (Cycle 9, Day 1), the last doses of cisplatin on December 30, 2010 (Cycle 6, Day 1), and the last dose of gemcitabine on January 6, 2010 (Cycle 6, Day 8). As per site phone conversation, the patient was taken off the study due to disease progression on March 3, 2011. He expired on April 5, 2011. At this time, there is no other information available. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drug.</b>		
13. DOSE, ROUTE, AND SCHEDULE <b>Cycle = 21 days</b> <b>Bevacizumab/placebo 15 mg/kg IV over 30-90 minutes on Day 1</b>		
14. DATES OF TREATMENT <b>The patient began the investigational therapy on September 9, 2010, and received the last dose of bevacizumab/placebo on March 3, 2011 (Cycle 9, Day 1).</b>		
15. ACCRUAL AND IND EXPERIENCE <b>Number of patients enrolled in NCI-sponsored clinical trials using bevacizumab = 31,666. There have been 172 other cases of deaths reported to the NCI as serious adverse events through AdEERS for bevacizumab.</b>		
16. COMMENTS <b>The following was also administered:</b> <b>Cisplatin 70 mg/m<sup>2</sup> IV on Day 1 and Gemcitabine 1000 mg/m<sup>2</sup> IV over 30 minutes on Days 1 and 8 for Cycles 1-6.</b>		
<b>AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d) (2).</b>		
<b>DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.</b>		